Skip to content
DataLookout
Menu

QoL in LSSCNCT07320820

Quality of Life and Functional Outcomes in Laryngeal Cancer Patients

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 2, 2027 to Jul 2, 2027 Show 4 more changesShow less
    • Start date: Apr 2, 2026 to Jan 2, 2027
    • Eligibility criteria expanded, about 9 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Secondary endpoints: details revised at 7 of 7 entries
  2. Notable Start date: Jan 2, 2026 to Apr 2, 2026v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Head and Neck-Specific Quality of Life (EORTC QLQ-H&N35)
Timeframe: Baseline (pre-treatment), 3 months, 6 months, and 12 months after completion of treatment. Type of Measure: Patient-reported outcome; continuous scale.

Secondary (7)

Change in Global Quality of Life (EORTC QLQ-C30)
Change in Swallowing Function (MD Anderson Dysphagia Inventory - MDADI)
Change in Patient Satisfaction (EORTC PATSAT-C33)
Change in Dysphagia Severity (Eating Assessment Tool - EAT-10)
Change in Voice-Related Handicap (Voice Handicap Index-10 - VHI-10)
Show 2 moreShow less
Change in Pain Intensity (Visual Analog Scale - VAS)
Change in Anxiety and Depression Levels (Hospital Anxiety and Depression Scale - HADS)

Arms and interventions

Surgical Treatment Group

This group includes patients with laryngeal squamous cell carcinoma who undergo primary surgical treatment, such as partial or total laryngectomy, with or without neck dissection, in accordance with standard oncological indications. Patients in this group may receive adjuvant radiotherapy or chemoradiotherapy when clinically indicated based on pathological findings.

Radiotherapy Group

This group consists of patients with laryngeal squamous cell carcinoma treated with definitive radiotherapy as the primary treatment modality. Radiotherapy is delivered according to established clinical protocols, and no surgical intervention to the primary tumor is performed as the initial treatment.

Chemoradiotherapy Group

This group includes patients with laryngeal squamous cell carcinoma who receive concurrent chemoradiotherapy as the primary treatment modality, typically for organ preservation purposes or in locally advanced disease. Chemotherapy is administered concurrently with radiotherapy in accordance with institutional and international treatment guidelines.

Other: Quality of Life Assessment, Patient Satisfaction Assessment, Swallowing Function Assessment, Voice Assessment, Pain Assessment, Anxiety and Depression Assessment